Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018

August 2018 | 30 pages | ID: C9C91801953EN
Global Markets Direct

Abstracts

Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018, provides an overview of the Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) pipeline landscape.

Chronic Traumatic Encephalopathy (CTE) is a degenerative brain disease found in athletes, military veterans, and others with a history of repetitive brain trauma. Symptoms include loss of consciousness, headache, drowsiness, convulsions and slurred speech, nausea or vomiting and unusual behavior. Risk factors include repeated exposure to traumatic brain injury.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Traumatic Encephalopathy (CTE) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chronic Traumatic Encephalopathy (CTE) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Traumatic Encephalopathy (CTE) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 6 respectively.

Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Traumatic Encephalopathy (CTE) (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Traumatic Encephalopathy (CTE) (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chronic Traumatic Encephalopathy (CTE) (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chronic Traumatic Encephalopathy (CTE) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Chronic Traumatic Encephalopathy (CTE) - Overview
Chronic Traumatic Encephalopathy (CTE) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chronic Traumatic Encephalopathy (CTE) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Traumatic Encephalopathy (CTE) - Companies Involved in Therapeutics Development
Eustralis Pharmaceuticals Ltd
Prothena Corp Plc
Tetra Discovery Partners LLC
Chronic Traumatic Encephalopathy (CTE) - Drug Profiles
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EUC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Tau for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-acetyl cysteine amide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PU-AD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Tau for Alzheimer's Disease and Chronic Traumatic Encephalopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chronic Traumatic Encephalopathy (CTE) - Product Development Milestones
Featured News & Press Releases
May 22, 2018: Dateline NBC Segment Features Medical Marijuana Portfolio Company Kannalife Sciences
May 18, 2018: Kannalife Sciences to be Featured in Dateline NBC Segment Covering Companys Research on CBD-Like Molecules as Treatments for HE, CTE
Jan 29, 2018: United Neuroscience Announces Development Plans for Vaccine to Prevent CTE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Traumatic Encephalopathy (CTE), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Chronic Traumatic Encephalopathy (CTE) - Pipeline by Eustralis Pharmaceuticals Ltd, H2 2018
Chronic Traumatic Encephalopathy (CTE) - Pipeline by Prothena Corp Plc, H2 2018
Chronic Traumatic Encephalopathy (CTE) - Pipeline by Tetra Discovery Partners LLC, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Traumatic Encephalopathy (CTE), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Eustralis Pharmaceuticals Ltd
Prothena Corp Plc
Tetra Discovery Partners LLC